Armata Pharmaceuticals (TG1N) Price & Analysis

Compare

1 Followers

TG1N Stock Chart & Stats

€7.05

-€0.01(-0.52%)

At close: Jan 08 4:00 PM EST

€7.05

-€0.01(-0.52%)

Day’s Range― - ―

52-Week Range€0.70 - €7.05

Previous CloseN/A

Volume0.00

Average Volume (3M)189.00

Market Cap

€250.50M

Enterprise Value€510.25M

Total Cash (Recent Filing)€14.76M

Total Debt (Recent Filing)€177.68M

Price to Earnings (P/E)―

Beta1.91

Next Earnings

Mar 19, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding36,406,906

10 Day Avg. Volume50

30 Day Avg. Volume189

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)-1.39

Price to Sales (P/S)12.93

P/FCF Ratio-1.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.68

Price Target Upside79.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 data showed the lead therapy added to standard antibiotics produced substantially better clinical responses with no evidence of relapse and a favorable safety profile, supporting the case for superiority in later trials.

Manufacturing ReadinessCommissioning of an in-house cGMP phage manufacturing facility with successful initial production runs provides operational capacity to support pivotal trials and potential commercial supply.

Regulatory PathwaySupportive FDA feedback on study design and potential eligibility for a Qualified Infectious Disease Product designation could enable priority review and added market exclusivity, strengthening the path toward a pivotal Phase 3 program.

Bears Say

Execution RiskInitiation of the pivotal trial depends on meeting regulatory, manufacturing, and operational milestones, so delays or unmet requirements could postpone development and raise costs.

Financing And Dilution RiskLimited cash resources increase the likelihood of raising additional capital, which could dilute existing shareholders and affect the company's financial flexibility.

Research Conflict Of InterestBusiness relationships between research firms and covered companies may create conflicts that could compromise the objectivity of analyst reports and investor guidance.

Armata Pharmaceuticals News

Armata price target raised to $15 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $15 from $9 and keeps a...

1d ago

ARMP

Armata Pharmaceuticals receives FDA QIDP designation for AP-SA02

Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted AP-SA02, the company’s Staphylococcus aureus multi-phage product candidate,...

1d ago

ARMP

Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy

Armata Pharmaceuticals ( ($ARMP) ) just unveiled an announcement. On February 23, 2026, Armata Pharmaceuticals announced that the...

1d ago

ARMP

Armata Extends Innoviva Credit, Warrants and Voting Pact

Armata Pharmaceuticals ( ($ARMP) ) just unveiled an update. On January 23, 2026, Armata Pharmaceuticals amended four existing...

29d ago

ARMP

Armata Pharmaceuticals: FDA-Endorsed Phase 3 Path and Potential QIDP Upside Support Buy Rating on AP-SA02

Armata Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from...

1M ago

ARMP

Armata Wins FDA Support to Advance Bacteriophage to Phase 3

The latest update is out from Armata Pharmaceuticals ( ($ARMP) ). On January 13, 2026, Armata Pharmaceuticals announced...

1M ago

ARMP

Armata Pharmaceuticals announces End-of-Phase 2 meeting with FDA

Armata Pharmaceuticals (ARMP) announced the conclusion of an End-of-Phase 2 written response from the U.S. FDA and plans...

1M ago

ARMP

Armata Pharmaceuticals initiated with a Buy at JonesResearch

JonesResearch analyst Debanjana Chatterjee initiated coverage of Armata Pharmaceuticals (ARMP) with a Buy rating and $15 price target...

2M ago

ARMP

Armata Pharmaceuticals Enters Capital Sales Agreement

Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On December 1, 2025, Armata Pharmaceuticals entered into a...

3M ago

ARMP

Armata Pharmaceuticals: Strategic Advancements and Clinical Progress Drive Buy Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Armata Pharmaceuticals. The associated price target...

3M ago

ARMP

Armata Pharmaceuticals reports Q3 EPS (74c) vs. (15c) last year

Reports Q3 revenue $1.2M vs. $3.0M last year. As of September 30, Armata held approximately $14.8M of unrestricted...

3M ago

ARMP

Armata Pharmaceuticals: Strategic Advancements and Operational Milestones Justify Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Armata Pharmaceuticals, retaining the price target of...

4M ago

ARMP

Armata Pharmaceuticals trading resumes

10:10 EST Armata Pharmaceuticals (ARMP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

4M ago

ARMP

Armata Pharmaceuticals trading halted, volatility trading pause

10:05 EST Armata Pharmaceuticals (ARMP) trading halted, volatility trading pause Published first on TheFly – the ultimate source...

4M ago

ARMP

TG1N FAQ

What was Armata Pharmaceuticals Inc’s price range in the past 12 months?

Armata Pharmaceuticals Inc lowest stock price was €0.70 and its highest was €7.05 in the past 12 months.

What is Armata Pharmaceuticals Inc’s market cap?

Armata Pharmaceuticals Inc’s market cap is €250.50M.

When is Armata Pharmaceuticals Inc’s upcoming earnings report date?

Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 23 days.

How were Armata Pharmaceuticals Inc’s earnings last quarter?

Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -€0.628 earnings per share for the quarter, missing the consensus estimate of -€0.356 by -€0.272.

Is Armata Pharmaceuticals Inc overvalued?

According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Armata Pharmaceuticals Inc pay dividends?

Armata Pharmaceuticals Inc does not currently pay dividends.

What is Armata Pharmaceuticals Inc’s EPS estimate?

Armata Pharmaceuticals Inc’s EPS estimate is -0.24.

How many shares outstanding does Armata Pharmaceuticals Inc have?

Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.

What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?

Armata Pharmaceuticals Inc reported an EPS of -€0.628 in its last earnings report, missing expectations of -€0.356. Following the earnings report the stock price went down -0.87%.

Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in DE:TG1N

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Armata Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-8.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Armata Pharmaceuticals (TG1N) Earnings & Revenues

Historic Earnings Reports

TG1N Stock 12 Month Forecast

Average Price Target

€12.68

▲(79.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","13":"€13","3.25":"€3.25","6.5":"€6.5","9.75":"€9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.6835521,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.6835521,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.6835521,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.05258093076923,6.605161861538462,7.157742792307692,7.7103237230769235,8.262904653846153,8.815485584615384,9.368066515384616,9.920647446153847,10.473228376923077,11.025809307692308,11.578390238461537,12.130971169230769,{"y":12.6835521,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.05258093076923,6.605161861538462,7.157742792307692,7.7103237230769235,8.262904653846153,8.815485584615384,9.368066515384616,9.920647446153847,10.473228376923077,11.025809307692308,11.578390238461537,12.130971169230769,{"y":12.6835521,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.05258093076923,6.605161861538462,7.157742792307692,7.7103237230769235,8.262904653846153,8.815485584615384,9.368066515384616,9.920647446153847,10.473228376923077,11.025809307692308,11.578390238461537,12.130971169230769,{"y":12.6835521,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >